Skip to content

Reduction of SystemiC Inflammation after ischemic stroke by intravenous DNase administration (ReSCInD)

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-516701-22-00
Acronym
RESCIND-1-2023
Enrollment
36
Registered
2024-10-31
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reduction of SystemiC Inflammation after ischemic stroke by intravenous DNase administration

Brief summary

The primary endpoint, IL-1 β concentration in the blood within 24±6 hrs after symptom onset, will be analyzed in the full analysis set, which comes as close as possible to the IIT principle. A mixed linear regression model is calculated with the IL-1 β value (at 24±6hrs & 3 d) as the dependent variable, the randomized group, the IL-1 β value at baseline & the time point, the interaction of time + group, as independent variables and the patient as a random effect.

Detailed description

All secondary endpoints are analyzed descriptively, and differences between the two study arms are explored according to their level of measurement.

Interventions

DRUGPulmozyme 2.500 E./2
DRUG5 ml
DRUGLösung für einen Vernebler
DRUGIsotonische Kochsalzlösung

Sponsors

Klinikum der Universitaet Muenchen AöR
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoint, IL-1 β concentration in the blood within 24±6 hrs after symptom onset, will be analyzed in the full analysis set, which comes as close as possible to the IIT principle. A mixed linear regression model is calculated with the IL-1 β value (at 24±6hrs & 3 d) as the dependent variable, the randomized group, the IL-1 β value at baseline & the time point, the interaction of time + group, as independent variables and the patient as a random effect.

Secondary

MeasureTime frame
All secondary endpoints are analyzed descriptively, and differences between the two study arms are explored according to their level of measurement.

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026